Characterizing Next-Generation Antibody Therapeutics: LC Strategies for Multispecifics, ADCs & AOCs
Modern biopharma pipelines are rapidly expanding beyond conventional monoclonal antibodies into multi‑specific formats and bioconjugates such as antibody–drug conjugates (ADCs) and antibody–oligonucleotide conjugates (AOCs). While these modalities unlock new therapeutic possibilities, their structural complexity significantly increases analytical demands. Molecular assembly, chain pairing, size, charge, and hydrophobic heterogeneity, post-translational modifications, and stability can all vary in subtle yet clinically meaningful ways.
In this webinar, we present a practical, end‑to‑end characterization framework that connects LC-based strategies across structural levels—intact, subunit, and peptide—and shows how orthogonal separations support confident decisions from development through QC transfer. Topics include approaches to verify structural integrity, reveal mispaired or incorrectly assembled species, monitor size variants and aggregation, assign charge variants, and apply fit‑for‑purpose workflows to conjugated antibodies where additional heterogeneity must be controlled.
Attendees will leave with a clear “analytical toolbox” perspective—understanding which techniques to apply, what questions each method answers, and how to assemble robust characterization strategies for emerging antibody modalities.
What you'll learn
- How multispecific formats and conjugates change analytical strategy vs. traditional mAbs
- How LC separates and quantifies variants, while LC–MS enables molecular confirmation
- How to align intact, subunit, and peptide workflows to specific analytical questions
- How conjugation introduces new heterogeneity—and how to manage it effectively (ADC/AOC)
Why attend?
As antibody therapeutics evolve from conventional mAbs to multi‑specific architectures and bioconjugates (ADCs and AOCs), analytical teams face complexity—more variants, more heterogeneity, and a greater need for orthogonal evidence to support confident development and control strategies.
In this webinar, we share a pragmatic characterization roadmap using LC-based methods across intact, subunit, and peptide‑mapping workflows—showing how each layer answers different questions, and how to assemble them into a cohesive package.
Key takeaways include:
- Selecting LC/LC‑MS approaches for size, charge, and hydrophobic variants,
- Detecting mispaired or incorrectly assembled multi‑specific species
- Handling the added complexity of conjugated antibodies (ADC/AOC) within fit‑for‑purpose workflows
Ideal for scientists in analytical development, CMC, and QC supporting next‑generation antibody therapeutics.
Who should attend?
Analytical scientists in biopharma R&D, process development, and QC working with advanced antibody modalities.
You can select the language of the content in the top right corner of your screen. This webinar will be delivered in English.
Speaker: Ali Tiss, Ph.D., MSc., Eng. (Chat) (Chemistry Market Development Manager, Biopharma & Cell and Gene Therapies, Waters Corporation)
Ali joined Waters in 2021 and has since supported colleagues and users in the biomolecule separation field (proteins, peptides, Abs, conjugates, Cell & Gene Therapy products). Ali completed his Ph.D. in biochemistry and structural biology at the Mediterranean University (CNRS, Marseille, France), where he contributed to the R&D of the anti-obesity drug, Xenical®, developed by Roche Ltd. Then, he earned over two decades of research experience in biochemistry, liquid chromatography, mass spectrometry, and proteomics, focusing on detecting and characterizing biomarkers related to human diseases such as cancer, diabetes, and obesity. Ali is passionate about supporting customer business and innovative applications.
